Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CINSARC AND SARCULATOR IN PATIENTS WITH PRIMARY RETROPERITONEAL SARCOMA: A COMBINED ANALYSIS OF SINGLE INSTITUTION DATA AND EORTC-STBSG-62092 TRIAL (STRASS).
Callegaro D, Tinè G, Oppong FB, Nzokirantevye A, Litière S, Percio S, Carenzo A, De Cecco L, Chibon F, Brich S, Bertolotti A, Collini P, Frezza AM, Huang P, Haas R, Bonvalot S, van Houdt WJ, Miceli R, Pasquali S, Gronchi A. Callegaro D, et al. Among authors: litiere s. Clin Cancer Res. 2025 May 27. doi: 10.1158/1078-0432.CCR-25-0099. Online ahead of print. Clin Cancer Res. 2025. PMID: 40423526
Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project.
Masson-Lecomte A, Grisay G, Damme JV, Achard V, Mertens LS, Boellaard TN, D'Haese D, Fournier B, Govaerts AS, Huddart R, Soria F, Dyrskjøt L, Allory Y, Pecoraro M, Litiere S, Tombal B, Panebianco V, Loriot Y. Masson-Lecomte A, et al. Among authors: litiere s. Eur Urol Oncol. 2025 Jun;8(3):603-607. doi: 10.1016/j.euo.2025.03.005. Epub 2025 Apr 16. Eur Urol Oncol. 2025. PMID: 40240255
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group.
Wyatt AW, Litiere S, Bidard FC, Cabel L, Dyrskjøt L, Karlovich CA, Pantel K, Petrie J, Philip R, Andrews HS, Vellanki PJ, Tolmeijer SH, Villalobos Alberu X, Alfano C, Bogaerts J, Calvo E, Chen AP, Toledo RA, de Vries EGE, Seymour L, Laurie SA, Garralda E; RECIST ctDNA workshop group. Wyatt AW, et al. Among authors: litiere s. Clin Cancer Res. 2024 Nov 15;30(22):5034-5041. doi: 10.1158/1078-0432.CCR-24-1883. Clin Cancer Res. 2024. PMID: 39269996 Review.
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
Leboulleux S, Kapiteijn E, Litière S, Schöffski P, Godbert Y, Rodien P, Jarzab B, Salvatore D, Zanetta S, Capdevila J, Bastholt L, De La Fouchardiere C, Lalami Y, Bardet S, Cornélis F, Dedecjus M, Links T, Sents W, Schlumberger M, Locati DL, Newbold K. Leboulleux S, et al. Among authors: litiere s. Front Endocrinol (Lausanne). 2024 Jun 27;15:1403687. doi: 10.3389/fendo.2024.1403687. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39015176 Free PMC article. Clinical Trial.
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
Hobor S, Al Bakir M, Hiley CT, Skrzypski M, Frankell AM, Bakker B, Watkins TBK, Markovets A, Dry JR, Brown AP, van der Aart J, van den Bos H, Spierings D, Oukrif D, Novelli M, Chakrabarti T, Rabinowitz AH, Ait Hassou L, Litière S, Kerr DL, Tan L, Kelly G, Moore DA, Renshaw MJ, Venkatesan S, Hill W, Huebner A, Martínez-Ruiz C, Black JRM, Wu W, Angelova M, McGranahan N, Downward J, Chmielecki J, Barrett C, Litchfield K, Chew SK, Blakely CM, de Bruin EC, Foijer F, Vousden KH, Bivona TG; TRACERx consortium; Hynds RE, Kanu N, Zaccaria S, Grönroos E, Swanton C. Hobor S, et al. Among authors: litiere s. Nat Commun. 2024 Jun 13;15(1):4871. doi: 10.1038/s41467-024-47606-9. Nat Commun. 2024. PMID: 38871738 Free PMC article.
Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.
Nakajima EC, Simpson A, Bogaerts J, de Vries EGE, Do R, Garalda E, Goldmacher G, Kinahan PE, Lambin P, LeStage B, Li Q, Lin F, Litière S, Perez-Lopez R, Petrick N, Schwartz L, Seymour L, Shankar L, Laurie SA. Nakajima EC, et al. Among authors: litiere s. JCO Precis Oncol. 2024 Apr;8:e2300687. doi: 10.1200/PO.23.00687. JCO Precis Oncol. 2024. PMID: 38635935
99 results